Wiecek A, Kokot F, Spiechowicz U, Cieplok J, Czerwieńska B, Strzelczyk P, Dyjas R
Katedry i Kliniki Nefrologii Slaskiej Akademii Medycznej w Katowicach.
Przegl Lek. 1996;53(12):866-9.
The present paper aimed to assess the influence of EPO-therapy on the requirement of blood transfusion in haemodialysed patients with end-stage renal failure. As shown in this paper, introduction of r-HuEPO into the therapy of uraemic anaemia almost completely eliminated the request for blood transfusion in these patients. EPO therapy did not influence significantly to the serum creatinine concentration and mean arterial blood pressure in these patients.
本研究旨在评估促红细胞生成素（EPO）治疗对终末期肾衰竭血液透析患者输血需求的影响。如本文所示，在尿毒症贫血治疗中引入重组人促红细胞生成素（r-HuEPO）几乎完全消除了这些患者的输血需求。EPO治疗对这些患者的血清肌酐浓度和平均动脉血压没有显著影响。
